Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Publication/Presentation Date

5-4-2018

Abstract

Chimeric antigen receptor (CAR) T cell therapy is genetically engineered tumor antigen-specific anticancer immunotherapy, which after showing great success in hematological malignancies is currently being tried in advanced solid tumors like pancreatic cancer. Immunosuppressive tumor microenvironment and dense fibrous stroma are some of the limitation in the success of this novel therapy. However, genetic modifications and combination therapy is the topic of the research to improve its efficacy. In this article, we summarize the current state of knowledge, limitations, and future prospects for CAR T cell therapy in pancreatic cancer.

Volume

35

Issue

6

First Page

84

Last Page

84

ISSN

1559-131X

Disciplines

Medicine and Health Sciences

PubMedID

29728788

Department(s)

Department of Obstetrics and Gynecology

Document Type

Article

Share

COinS